United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone 200 ug in 1 ml - milrinone lactate injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone lactate injection is contraindicated in patients who are hypersensitive to it.

United States - English - NLM (National Library of Medicine)

hospira, inc. - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7) - milrinone 200 ug in 1 ml - milrinone lactate injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life threatening ventricular arrhythmias, must be available. the majority of experience with milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone lactate is contraindicated in patients who are hypersensitive to it. to open tear outer wrap at notch and remove solution container. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. preparation for administration (use aseptic technique) - close flow control clamp of ad

United States - English - NLM (National Library of Medicine)

b. braun medical inc. - milrinone lactate (unii: 9k8xr81mo8) (milrinone - unii:ju9yax04c7), dextrose monohydrate (unii: lx22yl083g) (dextrose - unii:iy9xdz35w2) - injection - 200 ug in 1 ml - milrinone lactate in 5% dextrose injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. the facility for immediate treatment of potential cardiac events, which may include life-threatening ventricular arrhythmias, must be available. the majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. there is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. milrinone lactate in 5% dextrose injection is contraindicated in patients who are hypersensitive to milrinone. solutions containing dextrose may be contraindicated in patients with hypersensitivity to corn products.

United States - English - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - ammonium lactate (unii: 67m901l9nq) (lactic acid - unii:33x04xa5at) - lactic acid 12 g in 100 g - ammonium lactate cream, 12% is indicated for the treatment of ichthyosis vulgaris and xerosis. ammonium lactate cream, 12% is contraindicated in those patients with a history of hypersensitivity to any of the label ingredients.

United States - English - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - ammonium lactate (unii: 67m901l9nq) (lactic acid - unii:33x04xa5at) - lactic acid 12 g in 100 g - ammonium lactate lotion, 12% is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris, and for the temporary relief of itching associated with these conditions. ammonium lactate lotion, 12% is contraindicated in those patients with a history of hypersensitivity to any of the label ingredients.

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - cyclizine lactate, quantity: 50 mg/ml - injection - excipient ingredients: lactic acid; water for injections - valoid is indicated for the prevention of nausea and vomiting in the post operative period

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium chloride, quantity: 400 mg/l; sodium lactate, quantity: 3.22 g/l; calcium chloride dihydrate, quantity: 270 mg/l; sodium chloride, quantity: 6 g/l - injection, solution - excipient ingredients: sodium hydroxide; lactic acid; water for injections - is indicated as a source of water and electrolytes. it is also used in patients as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency. these solutions are indicated as methods of intravenous drug delivery, if the drugs are comparable with the solutions. this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - calcium chloride dihydrate, quantity: 270 mg/l; sodium lactate, quantity: 3.22 g/l; potassium chloride, quantity: 400 mg/l; sodium chloride, quantity: 6 g/l - injection, solution - excipient ingredients: sodium hydroxide; water for injections - is indicated as a source of water and electrolytes. it is also used in patients as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency. these solutions are indicated as methods of intravenous drug delivery, if the drugs are comparable with the solutions.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 50 g/l; sodium chloride, quantity: 6 g/l; sodium lactate, quantity: 3.22 g/l; potassium chloride, quantity: 400 mg/l; calcium chloride dihydrate, quantity: 270 mg/l - injection, solution - excipient ingredients: water for injections - compound sodium lactate solution and 5% glucose is indicated as a source of water and electrolytes. it is also used in patients as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency. these solutions are indicated as methods of intravenous drug delivery, if the drugs are compatible with the solutions.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 50 g/l; sodium chloride, quantity: 6 g/l; sodium lactate, quantity: 3.22 g/l; potassium chloride, quantity: 400 mg/l; calcium chloride dihydrate, quantity: 270 mg/l - injection, solution - excipient ingredients: water for injections - compound sodium lactate solution and 5% glucose is indicated as a source of water and electrolytes. it is also used in patients as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency. these solutions are indicated as methods of intravenous drug delivery, if the drugs are compatible with the solutions.